Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Polyrizon Ltd. (PLRZ) Stock · SELL · CRISIS | LOPJLB

Polyrizon Ltd. (PLRZ)

Healthcare · Biotechnology · NASDAQ · IL

$9.67+4.43%Close

SELLCRISIS · day 9

PLRZ▼ SELL

$9.67+4.43%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $11M
Beta: -1.34
P/E (TTM): -2.29

Short % float: 5.28%
Days to cover: 1.0
SI change: -19.0%

1W: -7.82%
1M: -13.97%

vs SPY 1W: -9.77%
vs SPY 1M: -15.38%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the…

Employees: 6
Headquarters: IL
Founded: 2024
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 1.1M
Float: 93.9%

polyrizon-biotech.com ↗

Key executives

Tomer Izraeli — Founder, Chief Executive Officer & Director

Tidhar Turgeman — Chief Technology Officer

Nir Ben Yosef — Chief Financial Officer & Compliance Officer

SEC filings

EDGAR · CIK 18936450 · PLRZ

All filings
10-K
10-Q
8-K
Form 4

Company news

globenewswire.com · 3d ago

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

globenewswire.com · 16d ago

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

globenewswire.com · 33d ago

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

globenewswire.com · 35d ago

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

globenewswire.com · 36d ago

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

globenewswire.com · 48d ago

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Market news & ticker search · RSS for PLRZ

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE